Drug Trial Radar · NCT02990481
A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Mar 6, 2017
Primary completion
Sep 16, 2019
Study completion Sep 16, 2019
Sponsor
- Lead sponsor
- Toray Industries, IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies
Conditions
- Locally Advanced or Metastatic Solid Carcinomas
- Colon Cancer
- Cholangiocarcinoma
Interventions
TRK-950Biological
Intravenously over 60 minutes, on day 1, 8 and 15 of each cycle
TRK-950Biological
Low dose: intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle High dose: intravenously over 60 minutes, on day 1 and 15 of each cycle
TRK-950Biological
Low dose: Intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventTime frame: through study completion, an average of 1 year
- CTCAE version 4.03Time frame: through study completion, an average of 1 year
- Blood pressure (mmHg)Time frame: through study completion, an average of 1 year
- Heart rate (bpm)Time frame: through study completion, an average of 1 year
- Respiratory rate (bpm)Time frame: through study completion, an average of 1 year
- Temperature (°F or °C)Time frame: through study completion, an average of 1 year
- Weight (lbs/kg)Time frame: through study completion, an average of 1 year
- Height (inches/cm)Time frame: through study completion, an average of 1 year
- Karnofsky performance statusTime frame: through study completion, an average of 1 year
- ElectrocardiogramTime frame: through study completion, an average of 1 year
- Clinical laboratory testsTime frame: through study completion, an average of 1 year
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona
HonorHealth Research Institute
Scottsdale, Arizona
Centre Léon Bérard
Lyon, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.